How to Screen Biotech Stocks with Natural Language: Beyond Traditional Stock Screeners

The Problem with Traditional Biotech Screening

Traditional stock screeners were built for general equities. They let you filter by market cap, P/E ratio, revenue growth, and other standard financial metrics. But biotech companies — especially pre-revenue, clinical-stage ones — don't fit neatly into these boxes.

Consider what a biotech investor actually wants to know:

• "Which companies have a PDUFA date in the next 90 days?"
• "Show me oncology companies with Phase 3 trials that met their primary endpoint"
• "Find biotechs with more than 24 months of cash runway and a Breakthrough Therapy Designation"
• "Which companies had insider buying in the last 30 days?"

None of these queries work in traditional screeners. They require cross-referencing clinical trial databases, FDA records, SEC filings, and financial data — all at once.

What Is Natural Language Screening?

Natural language screening uses AI to translate plain English (or any language) queries into structured database filters. Instead of navigating complex dropdown menus and checkbox-based interfaces, you type what you're looking for in your own words.

The system parses your intent, maps it to available data fields, and returns matching companies — all in seconds.

How It Works Under the Hood

1. Query parsing: An NL compiler analyzes your text to identify the intent, entities (drug names, company names, therapeutic areas), and filter conditions (thresholds, date ranges, comparisons)
2. Field mapping: The parsed intent is mapped to the corresponding database fields across multiple data sources (financial data, clinical trials, FDA events, SEC filings)
3. Query execution: The structured query runs against the full company database
4. Result ranking: Results are sorted by relevance to your query, with the strongest matches first
5. Explanation: The system shows you what filters were applied, so you can verify the interpretation

Examples of Natural Language Queries

Natural Language Query	What Gets Filtered
"Oncology companies with market cap under $2B"	therapeutic_focus = oncology, market_cap < 2B
"Phase 3 trials reporting data this quarter"	trial_phase = 3, data_readout_date within quarter
"Companies with Breakthrough Therapy Designation"	fda_designation includes BTD
"Cash runway above 18 months"	calculated runway > 18 months
"Recent FDA approvals in rare disease"	fda_decision = approved, orphan = true, recent
"Insider buying last 60 days"	insider_transactions type=purchase, last 60 days
"Small cap biotechs with upcoming PDUFA"	market_cap < 2B, pdufa_date upcoming

Why Natural Language Beats Traditional Screeners for Biotech

Multi-Source Queries

Traditional screeners pull from one data source (usually financial data only). Natural language screening queries across:

• Financial data: Market cap, cash, burn rate, revenue
• Clinical trial data: Phase, status, endpoints, enrollment
• Regulatory data: FDA designations, PDUFA dates, approval history
• SEC filings: Insider transactions, risk factors, financial disclosures
• Scientific data: Publications, patent filings, mechanism of action

A single natural language query can combine filters from all of these sources simultaneously.

Iterative Refinement

Natural language screening supports conversational refinement:

1. "Show me oncology biotechs" → Initial broad results
2. "Only Phase 2 and above" → Narrow to late-stage
3. "With cash runway over 2 years" → Financial filter added
4. "Exclude companies with CRLs" → Remove recent regulatory setbacks

Each step builds on the previous query, making it easy to progressively narrow your search.

Accessible to Non-Technical Investors

You don't need to know database query syntax, API parameters, or the exact field names used in ClinicalTrials.gov. If you can describe what you want in plain language, the system handles the translation.

Building Effective Screening Strategies

Start Broad, Then Narrow

The most effective approach is to start with a broad category and progressively add filters:

1. Therapeutic area: "Oncology companies" or "Rare disease biotechs"
2. Development stage: "With Phase 3 or commercial-stage drugs"
3. Financial health: "Cash runway above 18 months"
4. Catalyst proximity: "With a catalyst in the next 6 months"
5. Quality signals: "With insider buying" or "With Breakthrough Therapy Designation"

Combine Positive and Negative Filters

Smart screening includes both what you want and what you want to avoid:

• "Oncology companies with Phase 3 data expected this year, excluding those with recent CRLs or less than 12 months cash runway"
• "Biotech companies with PDUFA dates in Q3, not including those where the AdCom vote was negative"

Save and Reuse Strategies

Once you've developed a screening query that works, save it as a reusable strategy. This lets you:

• Monitor changes: Run the same screen weekly to see new companies that match
• Track departures: Notice when companies you're watching no longer meet your criteria
• Share with collaborators: Team members can apply the same screening logic

Custom Strategies: Beyond Screening

Natural language screening is the first step. Advanced users can build complete investment strategies that combine screening with scoring and prioritization:

• Weighted scoring: "Score companies based on: cash runway (30%), Phase 3 proximity (25%), insider buying (20%), unmet medical need (25%)"
• Automated monitoring: "Alert me when any company matching this screen has a new 8-K filing or FDA event"
• Portfolio construction: "From the top 10 results, show me which have uncorrelated catalysts for diversification"

The Future of Biotech Research

Natural language screening represents a fundamental shift in how biotech investors discover opportunities. Instead of spending hours manually cross-referencing databases, investors can articulate their thesis in plain language and instantly see which companies match.

The key insight is that every data field — from clinical trial enrollment numbers to patent expiration dates to FDA meeting schedules — becomes a queryable dimension. This democratizes access to the kind of multi-factor analysis that was previously available only to institutional investors with dedicated data teams.

Summary

Natural language screening eliminates the biggest friction point in biotech investing: the gap between what you want to know and what traditional tools can tell you. By translating plain English queries into multi-source database filters, it makes comprehensive biotech screening accessible to any investor.

Try natural language biotech screening with BioSniper's free tier — screen up to 5 times per day with no credit card required.